Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 12/2008

01-12-2008 | Case Report

Abatacept and serious respiratory infections in patients with previous lung disease

Authors: Karla L. Miller, Allen D. Sawitzke, John Doane

Published in: Clinical Rheumatology | Issue 12/2008

Login to get access

Abstract

Abatacept is a biologic agent used in the treatment of rheumatoid arthritis, for which underlying chronic obstructive lung disease is listed as a precaution to its use due to concern for increased risk of respiratory adverse events. We describe two cases of severe respiratory complications affecting rheumatoid arthritis patients undergoing treatment with abatacept who had been previously diagnosed with underlying lung disease.
Literature
1.
Choy E, Panayi G (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Eng J Med 344:907–916CrossRef
2.
Weinblatt M, Combe B, Covucci A et al (2006) Safety of the selective costimulation modulator abacept in rheumatoid arthritis patients receiving background biologic and non biologic disease-modifying antirheumatic drugs. Arthritis Rheum 54:2807–2816PubMedCrossRef
3.
Kremer J, Dougados M, Emery P et al (2005) Treatment of rheumatoid arthritis with the seclective costimulation modulator abacept: twelve month results of a phase IIb double blind randomized, placebo-controlled trial. Arthritis Rheum 52:2263–2271PubMedCrossRef
4.
Genovese M, Becker J, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Eng J Med 353(21):1114–1123CrossRef
5.
6.
7.
Ananthakrishnan AN, Attila T et al (2007) Severe pulmonary toxicity after azathiprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 41(7):682–688PubMedCrossRef
8.
Zimmer C, Beiderlinden M et al (2006) Lethal acute respiratory distress syndrome during anti-TNF-α therapy for rheumatoid arthritis. Clin Rheumatol 25:430–432PubMedCrossRef
9.
Dixon WG, Watson K et al (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 54:2368–2376PubMedCrossRef
10.
Blake GH, Abell TD et al (1988) Cigarette smoking and upper respiratory infection among recruits in basic combat training. Ann Intern Med 109:198–202PubMed
11.
Willemse BWM, ten Hacken NHT et al (2005) Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 26:835–845PubMedCrossRef
Metadata
Title
Abatacept and serious respiratory infections in patients with previous lung disease
Authors
Karla L. Miller
Allen D. Sawitzke
John Doane
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 12/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0979-9

Other articles of this Issue 12/2008

Clinical Rheumatology 12/2008 Go to the issue

Original Article

The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function

Original Article

Primary Sjögren’s syndrome in men: clinical and immunological characteristic based on a large cohort of Hungarian patients

Letter to the Editor

Etanercept tolerance in a patient with previous infliximab-induced hepatitis

Original Article

Efficacy of early dental and ENT therapy in preventing nephropathy in pediatric Henoch-Schönlein purpura

Original Article

Effects of external qigong therapy on osteoarthritis of the knee

Brief Report

Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits